Pharmacological and nutritional therapy of children and adults with chronic intestinal pseudo-obstruction

References

• Thapar N, Saliakellis E, Benninga MA, et al. Paediatric Intestinal Pseudo-obstruction: evidence and Consensus-based Recommendations From an ESPGHAN-Led Expert Group. J Pediatr Gastroenterol Nutr. 2018;66(6):991–1019.
   PubMed Web of Science ®Google Scholar
• Amiot A, Cazals-Hatem D, Joly F, et al. The role of immunohistochemistry in idiopathic chronic intestinal pseudoobstruction (CIPO): a case-control study. Am J Surg Pathol. 2009;33:749–758.
   PubMed Web of Science ®Google Scholar
• Vargas JH, Sachs P, Ament ME. Chronic intestinal pseudo-obstruction syndrome in pediatrics. Results of a national survey by members of the North American society of pediatric gastroenterology and nutrition. J Pediatr Gastroenterol Nutr. 1988;7:323–332.
   PubMedGoogle Scholar
• Iida H, Ohkubo H, Inamori M, et al. Epidemiology and clinical experience on chronic intestinal pseudo-obstruction in Japan: a nationwide epidemiologic survey. J Epidemiol. 2013;23:288‐94.
   PubMedGoogle Scholar
• Di Lorenzo C. Pseudo-obstruction: current approaches. Gastroenterology 1999;116:980–987.
   PubMed Web of Science ®Google Scholar
• Muto M, Matsufuji H, Tomomasa T, et al. Pediatric chronic intestinal pseudo-obstruction is a rare, serious, and intractable disease: a report of a nationwide survey in Japan. J Pediatr Surg. 2014;49:1799–1803.
   PubMedGoogle Scholar
• Stanghellini V, Cogliandro RF, De Giorgio R, et al. Natural history of chronic idiopathic intestinal pseudo-obstruction in adults: a single center study. Clin Gastroenterol Hepatol. 2005;3:449–458.
   PubMed Web of Science ®Google Scholar
• Stanghellini V, Cogliandro RF, de Giorgio R, et al. Chronic intestinal pseudo-obstruction: manifestations, natural history and management. Neurogastroenterol Motil. 2007;19:440–452.
   PubMed Web of Science ®Google Scholar
• Stanghellini V, Corinaldesi R, Barbara L. Pseudo-obstruction syndromes. Baillieres Clin Gastroenterol. 1988;2:225–254
   PubMedGoogle Scholar
• De Giorgio R, Cogliandro RF, Barbara G, et al. Chronic intestinal pseudo-obstruction: clinical features, diagnosis, and therapy. Gastroenterol Clin North Am. 2011;40(4):787–807.
   PubMed Web of Science ®Google Scholar
• Gabbard SL, Lacy BE. Chronic intestinal pseudo-obstruction. Nutr Clin Pract. 2013;28:307–316.
   PubMed Web of Science ®Google Scholar
• Yeung AK, Di Lorenzo C. Primary gastrointestinal motility disorders in childhood. Minerva Pediatr. 2012;64:567–584.
   PubMedGoogle Scholar
• Connor FL, Di Lorenzo C. Chronic intestinal pseudo-obstruction: assessment and management. Gastroenterology. 2006;130:29–36.
   PubMed Web of Science ®Google Scholar
• Di Nardo G, Di Lorenzo C, Lauro A, et al. Chronic intestinal pseudo-obstruction in children and adults: diagnosis and therapeutic options. Neurogastroenterol Motil. 2017;29.
   Google Scholar
• Lindberg G. Pseudo-obstruction, enteric dysmotility and irritable bowel syndrome. Best Pract Res Clin Gastroenterol. 2019;40–41:101635.
   PubMed Web of Science ®Google Scholar
• Mann SD, Debinski HS, Kamm MA. Clinical characteristics of chronic idiopathic intestinal pseudo-obstruction in adults. Gut. 1997;41:675–681.
   PubMed Web of Science ®Google Scholar
• Heneyke S, Smith VV, Spitz L, et al. Chronic intestinal pseudo-obstruction: treatment and long term follow-up of 44 patients. Arch Dis Child. 1999;81:21–27.
   PubMed Web of Science ®Google Scholar
• Stanghellini V, Camilleri M, Malagelada JR. Chronic idiopathic intestinal pseudo-obstruction: clinical and intestinal manometric findings. Gut. 1987;28:5–12.
   PubMed Web of Science ®Google Scholar
• Di Lorenzo C, Youssef NN. Diagnosis and management of intestinal motility disorders. Semin Pediatr Surg. 2010;19:50–58.
   PubMed Web of Science ®Google Scholar
• Di Lorenzo C, Lucanto C, Flores AF, et al. Effect of sequential erythromycin and octreotide on antroduodenal manometry. J Pediatr Gastroenterol Nutr. 1999;29:293–296.
   PubMedGoogle Scholar
• Knowles CH, Lindberg G, Panza E, et al. New perspectives in the diagnosis and management of enteric neuropathies. Nat Rev Gastroenterol Hepatol. 2013;10:206–218.
   PubMed Web of Science ®Google Scholar
• Lipton AB, Knauer CM. Pseudo-obstruction of the bowel. Therapeutic trial of metoclopramide. Am J Dig Dis. 1977;22:263–265.
   PubMedGoogle Scholar
• Longo WE, Vernava AM 3rd. Prokinetic agents for lower gastrointestinal motility disorders. Dis Colon Rectum. 1993;36::696–708.
   PubMed Web of Science ®Google Scholar
• Chini P, Toskes PP, Waseem S, et al. Effect of azithromycin on small bowel motility in patients with gastrointestinal dysmotility. Scand J Gastroenterol. 2012;47:422–427.
   PubMed Web of Science ®Google Scholar
• Sorhaug S, Steinshamn SL, Waldum HL. Octreotide treatment for paraneoplastic intestinal pseudo-obstruction complicating SCLC. Lung Cancer. 2005;48:137–140.
   PubMed Web of Science ®Google Scholar
• Acosta A, Camilleri M. Prokinetics in gastroparesis. Gastroenterol Clin North Am. 2015;44:97–111.
   PubMed Web of Science ®Google Scholar
• Camilleri M, Atieh J. New Developments in Prokinetic Therapy for Gastric Motility Disorders. Front Pharmacol. 2021;12:711500.
   PubMed Web of Science ®Google Scholar
• Hirsh EH, Brandenburg D, Hersh T, et al. Chronic intestinal pseudo-obstruction. J Clin Gastroenterol. 1981;3:247–254.
   PubMed Web of Science ®Google Scholar
• Turgeon DK. Domperidone in chronic intestinal pseudo-obstruction. Gastroenterology. 1990;99:1194.
   PubMedGoogle Scholar
• Cavero-Redondo I, Álvarez-Bueno C, Pozuelo-Carrascosa DP, et al. Risk of extrapyramidal side effects comparing continuous vs. bolus intravenous metoclopramide administration: a systematic review and meta-analysis of randomised controlled trials. J Clin Nurs. 2015;24:3638–3646.
   PubMedGoogle Scholar
• Stoetzer C, Voelker M, Doll T, et al. Cardiotoxic antiemetics metoclopramide and domperidone block cardiac voltage-gated Na+ channels. Anesth Analg. 2017;124:52–60.
   PubMedGoogle Scholar
• Ou LB, Moriello C, Douros A, et al. Domperidone and the risks of sudden cardiac death and ventricular arrhythmia: a systematic review and meta-analysis of observational studies. Br J Clin Pharmacol. 2021;87:3649–3658.
   PubMedGoogle Scholar
• Law NM, Bharucha AE, Undale AS, et al. Cholinergic stimulation enhances colonic motor activity, transit, and sensation in humans. Am J Physiol Gastrointest Liver Physiol. 2001;281:G1228–G1237.
   PubMedGoogle Scholar
• Chaudhary NA, Truelove SC. Human colonic motility: a comparative study of normal subjects, patients with ulcerative colitis, and patients with the irritable colon syndrome. II. The effect of prostigmin. Gastroenterology. 1961;40:18–26.
   PubMed Web of Science ®Google Scholar
• Valle RG, Godoy FL. Neostigmine for acute colonic pseudo-obstruction: a meta-analysis. Ann Med Surg (Lond). 2014;19:60–64.
   Google Scholar
• Gmora S, Poenaru D, Tsai E. Neostigmine for the treatment of pediatric acute colonic pseudo-obstruction. J Pediatr Surg. 2002;37:E28.
   PubMedGoogle Scholar
• De Giorgio R, Knowles CH. Acute colonic pseudo-obstruction. Br J Surg. 2009;96:229–239.
   PubMed Web of Science ®Google Scholar
• Lee JW, Bang KW, Jang PS, et al. Neostigmine for the treatment of acute colonic pseudo-obstruction (ACPO) in pediatric hematologic malignancies. Korean J Hematol. 2010;45:62–65.
   PubMedGoogle Scholar
• Calvet X, Martinez JM, Martinez M. Repeated neostigmine dosage as palliative treatment for chronic colonic pseudo-obstruction in a patient with autonomic paraneoplastic neuropathy. Am J Gastroenterol. 2003;98:708–709.
   PubMedGoogle Scholar
• O’Dea CJ, Brookes JH, Wattchow DA. The efficacy of treatment of patients with severe constipation or recurrent pseudo-obstruction with pyridostigmine. Colorectal Dis. 2010;12:540–548.
   PubMed Web of Science ®Google Scholar
• Boybeyi O, Ciftçi AO, Topaloğlu H. An unusual presentation of gastrointestinal obstruction in a three-year-old boy. Turk J Pediatr. 2009;51:195–198.
   PubMedGoogle Scholar
• Choudhury A, Rahyead A, Kammermeier J, et al. The use of pyridostigmine in a child with chronic intestinal pseudo-obstruction. Pediatrics. 2018;141(Suppl5):S404–S407.
   PubMedGoogle Scholar
• Manini ML, Camilleri M, Grothe R, et al. Application of pyridostigmine in pediatric gastrointestinal motility disorders: a case series. Paediatr Drugs. 2018;20:173–180.
   PubMedGoogle Scholar
• Lee H, Park S, Oh JT, et al. Oral pyridostigmine-responsive visceral myopathy with ACTG2 mutations: a case series. J Pediatr Gastroenterol Nutr. 2019;68:e16–e17.
   PubMedGoogle Scholar
• Di Nardo G, Viscogliosi F, Esposito F, et al. Pyridostigmine in pediatric intestinal pseudo-obstruction: case report of a 2-year-old girl and literature review. J Neurogastroenterol Motil. 2019;25:508–514.
   PubMedGoogle Scholar
• Maggi L, Mantegazza R. Treatment of myasthenia gravis: focus on pyridostigmine. Clin Drug Investig. 2011;31:691–701.
   PubMed Web of Science ®Google Scholar
• Spencer NJ, Hu H. Enteric nervous system: sensory transduction, neural circuits and gastrointestinal motility. Nat Rev Gastroenterol Hepatol. 2020;17:338–351.
   PubMed Web of Science ®Google Scholar
• Gershon MD. 5-Hydroxytryptamine (serotonin) in the gastrointestinal tract. Curr Opin Endocrinol Diabetes Obes. 2013;20:14–21.
   PubMed Web of Science ®Google Scholar
• Mawe GM, Hoffman JM. Serotonin signalling in the gut-functions, dysfunctions and therapeutic targets. Nat Rev Gastroenterol Hepatol. 2013;10:473–486.
   PubMed Web of Science ®Google Scholar
• Mohammad S, Zhou Z, Gong Q, et al. Blockage of the HERG human cardiac K + channel by the gastrointestinal prokinetic agent cisapride. Am J Physiol Hear Circ Physiol. 1997;273:H2534–8.
   PubMed Web of Science ®Google Scholar
• Wysowski DK, Corken A, Gallo-Torres H, et al. Post-marketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and FDA regulatory actions. Am J Gastroenterol. 2001;96:1698–1703.
   PubMed Web of Science ®Google Scholar
• De Maeyer JH, Lefebvre RA, Schuurkes JA. 5-HT4 receptor agonists: similar but not the same. Neurogastroenterol Motil. 2008;20:99–112.
   PubMed Web of Science ®Google Scholar
• Sayuk GS, Tack J. Tegaserod: what’s old is new again. Clin Gastroenterol Hepatol. 2022;20(2175–2184):e19.
   PubMedGoogle Scholar
• Bouras EP, Camilleri M, Burton DD, et al. Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder. Gastroenterology. 2001;120:354–360.
   PubMed Web of Science ®Google Scholar
• Chapman H, Pasternack M. The action of the novel gastrointestinal prokinetic prucalopride on the HERG K+ channel and the common T897 polymorph. Eur J Pharmacol. 2007;554:98–105.
   PubMed Web of Science ®Google Scholar
• Diederen K, Mugie SM, Benninga MA. Efficacy and safety of prucalopride in adults and children with chronic constipation. Expert Opin Pharmacother. 2015;16:407–416.
   PubMed Web of Science ®Google Scholar
• Winter HS, Di Lorenzo C, Benninga MA, et al. Oral prucalopride in children with functional constipation. J Pediatr Gastroenterol Nutr. 2013;57:197–203.
   PubMed Web of Science ®Google Scholar
• Camilleri M, Beyens G, Kerstens R, et al. Safety assessment of prucalopride in elderly patients with constipation: a double-blind, placebo-controlled study. Neurogastroenterol Motil. 2009;21:1256–e117.
   PubMed Web of Science ®Google Scholar
• Potet F, Bouyssou T, Escande D, et al. Gastrointestinal prokinetic drugs have different affinity for the human cardiac human ether-a-gogo K(+) channel. J Pharmacol Exp Ther. 2001;299:1007–1012.
   PubMed Web of Science ®Google Scholar
• Mendzelevski B, Ausma J, Chanter DO, et al. Assessment of the cardiac safety of prucalopride in healthy volunteers: a randomized, double-blind, placebo- and positive-controlled thorough QT study. Br J Clin Pharmacol. 2012;73:203–209.
   PubMed Web of Science ®Google Scholar
• Kessing BF, Smout AJ, Bennink RJ, et al. Prucalopride decreases esophageal acid exposure and accelerates gastric emptying in healthy subjects. Neurogastroenterol Motil. 2014;26:1079–1086.
   PubMed Web of Science ®Google Scholar
• Emmanuel AV, Kamm MA, Roy AJ, et al. Effect of a novel prokinetic drug, R093877, on gastrointestinal transit in healthy volunteers. Gut. 1998;42:511–516.
   PubMed Web of Science ®Google Scholar
• Tack J, Outryve MV, Beyens G, et al. Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives. Gut 2008;58:357–365.
   PubMed Web of Science ®Google Scholar
• Camilleri M, Kerstens R, Rykx A, et al. A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med. 2008;358:2344–2354.
   PubMed Web of Science ®Google Scholar
• Quigley EM, Vandeplassche L, Kerstens R, et al. Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation–a 12-week, randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther. 2009;29:315–328.
   PubMed Web of Science ®Google Scholar
• Smart CJ, Ramesh AN. The successful treatment of acute refractory pseudo-obstruction with prucalopride. Colorectal Dis. 2012;14:e508.
   PubMed Web of Science ®Google Scholar
• Giglio MC, Luglio G, Tarquini R, et al. Role of prucalopride in treatment of chronic constipation and recurrent functional obstruction in a patient with Steinert myotonic dystrophy. J Clin Gastroenterol. 2015;49:85–86.
   PubMed Web of Science ®Google Scholar
• Emmanuel AV, Kamm MA, Roy AJ, et al. Randomized clinical trial: the efficacy of prucalopride in patients with chronic intestinal pseudo-obstruction-a double-blind, placebo-controlled, crossover, multiple n = 1 study. Aliment Pharmacol Ther. 2012;35:48–55.
   PubMed Web of Science ®Google Scholar
• Bianco F, Bonora E, Natarajan D, et al. Prucalopride exerts neuroprotection in human enteric neurons. Am J Physiol Gastrointest Liver Physiol. 2016;310:G768–75.
   PubMedGoogle Scholar
• Kitazawa T, Kaiya H. Motilin comparative study: structure, distribution, receptors, and gastrointestinal motility. Front Endocrinol (Lausanne). 2021;12:700884.
   PubMedGoogle Scholar
• Catnach SM, Fairclough PD. Erythromycin and the gut. Gut 1992;33:397–401.
   PubMed Web of Science ®Google Scholar
• Venkatasubramani N, Rudolph CD, Sood MR. Erythromycin lacks colon prokinetic effect in children with functional gastrointestinal disorders: a retrospective study. BMC Gastroenterol. 2008;8:38.
   PubMedGoogle Scholar
• Minami T, Nishibayashi H, Shinomura Y, et al. Effects of erythromycin in chronic idiopathic intestinal pseudo-obstruction. J Gastroenterol. 1996;31:855–859.
   PubMedGoogle Scholar
• Curry JI, Lander TD, Stringer MD. Review article: erythromycin as a prokinetic agent in infants and children. Aliment Pharmacol Ther. 2001;15:595–603.
   PubMedGoogle Scholar
• Depoortere I, Peeters TL, Vantrappen G. Distribution and characterization of motilin receptors in the cat. Peptides 1993;14:1153–1157.
   PubMedGoogle Scholar
• Weber FH, Richards RD, McCallum RW. Erythromycin: a motilin agonist and gastrointestinal prokinetic agent. Am J Gastroenterol. 1993;88:485–490.
   PubMed Web of Science ®Google Scholar
• Thielemans L, Depoortere I, Perret J, et al. Desensitization of the human motilin receptor by motilides. J Pharmacol Exp Ther. 2005;313:1397–1405.
   PubMed Web of Science ®Google Scholar
• Dranove J, Horn D, Reddy SN, et al. Effect of intravenous erythromycin on the colonic motility of children and young adults during colonic manometry. J Pediatr Surg. 2010;45:777–783.
   PubMedGoogle Scholar
• Emmanuel AV, Shand AG, Kamm MA. Erythromycin for the treatment of chronic intestinal pseudo-obstruction: description of six cases with a positive response. Aliment Pharmacol Ther. 2004;19:687–694.
   PubMed Web of Science ®Google Scholar
• Rea E, Husbands E. Erythromycin: prophylaxis against recurrent small bowel obstruction. BMJ Support Palliat Care. 2017;7:261–263
   PubMedGoogle Scholar
• Ray WA, Murray KT, Meredith S, et al. Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med. 2004;351:1089–1096.
   PubMed Web of Science ®Google Scholar
• Mougey EB, Saunders M, Franciosi JP, et al. Comparative effectiveness of intravenous azithromycin versus erythromycin stimulating antroduodenal motility in children. J Pediatr Gastroenterol Nutr. 2022;74:25–32.
   PubMedGoogle Scholar
• Shakir AK, Altaf MA. Azithromycin induces migrating motor complexes in pediatric patients undergoing antroduodenal motility studies. J Pediatr Pharmacol Ther. 2018;23:390–394.
   PubMedGoogle Scholar
• Gomez R, Fernandez S, Aspirot A, et al. Effect of amoxicillin/clavulanate on gastrointestinal motility in children. J Pediatr Gastroenterol Nutr. 2012;54:780–784.
   PubMed Web of Science ®Google Scholar
• Van den Houte K, Scarpellini E, Verbeure W, et al. The role of GI peptides in functional dyspepsia and gastroparesis: a systematic review. Front Psychiatry. 2020;11:172.
   PubMed Web of Science ®Google Scholar
• Van Op den Bosch J, Adriaensen D, Van Nassauw L, et al. The role(s) of somatostatin, structurally related peptides and somatostatin receptors in the gastrointestinal tract: a review. Regul Pept. 2009;156:1–8.
   PubMedGoogle Scholar
• Katz MD, Erstad BL. Octreotide, a new somatostatin analogue. Clin Pharm. 1989;8:255–273.
   PubMedGoogle Scholar
• Soudah HC, Hasler WL, Owyang C. Effect of octreotide on intestinal motility and bacterial overgrowth in scleroderma. N Engl J Med. 1991;325:1461–1467.
   PubMed Web of Science ®Google Scholar
• Foxx-Orenstein A, Camilleri M, Stephens D, et al. Effect of a somatostatin analogue on gastric motor and sensory functions in healthy humans. Gut 2003;52:1555–1561.
   PubMed Web of Science ®Google Scholar
• Verne GN, Eaker EY, Hardy E, et al. Effect of octreotide and erythromycin on idiopathic and scleroderma-associated intestinal pseudo-obstruction. Dig Dis Sci. 1995;40:1892–1901.
   PubMed Web of Science ®Google Scholar
• Lanting PJ, Kruijsen MW, Rasher JJ, et al. Severe intestinal pseudoobstruction in a patient with systemic sclerosis. Successful treatment with octreotide. J Rheumatol. 1993;20:2175.
   PubMedGoogle Scholar
• Kobayashi T, Kobayashi M, Naka M, et al. Response to octreotide of intestinal pseudoobstruction and pneumatosis cystoides intestinalis associated with progressive systemic sclerosis. Intern Med. 1993;32:607–609.
   PubMedGoogle Scholar
• Nikou GC, Toumpanakis C, Katsiari C, et al. Treatment of small intestinal disease in systemic sclerosis with octreotide: a prospective study in seven patients. J Clin Rheumatol. 2007;13:119–123.
   PubMed Web of Science ®Google Scholar
• Perlemuter G, Cacoub P, Chaussade S, et al. Octreotide treatment of chronic intestinal pseudoobstruction secondary to connective tissue diseases. Arthritis Rheum. 1999;42:1545–1549.
   PubMed Web of Science ®Google Scholar
• Cogliandro RF, Rizzoli G, Bellacosa L, et al. Is gastroparesis a gastric disease? Neurogastroenterol Motil. 2019;31:e13562.
   PubMedGoogle Scholar
• Edmunds MC, Chen JD, Soykan I, et al. Effect of octreotide on gastric and small bowel motility in patients with gastroparesis. Aliment Pharmacol Ther. 1998;12:167–174.
   PubMedGoogle Scholar
• Sharma S, Ghoshal UC, Bhat G, et al. Gastric adenocarcinoma presenting with intestinal pseudo-obstruction, successfully treated with octreotide. Indian J Med Sci. 2006;60:467–470
   PubMedGoogle Scholar
• Ambartsumyan L, Flores A, Nurko S, et al. Utility of octreotide in advancing enteral feeds in children with chronic intestinal pseudo-obstruction. Paediatr Drugs. 2016;18:387–392
   PubMedGoogle Scholar
• Bushyhead D, Quigley EMM. Small intestinal bacterial overgrowth-pathophysiology and its implications for definition and management. Gastroenterology. 2022;163:593–607.
   PubMedGoogle Scholar
• Khan MZ, Lyu R, McMichael J, et al. Chronic intestinal pseudo-obstruction is associated with intestinal methanogen overgrowth. Digest Dis Sci. 2022;67(10)4834–4840.
   PubMedGoogle Scholar
• Di Stefano M, Miceli E, Missanelli A, et al. Absorbable vs. non-absorbable antibiotics in the treatment of small intestine bacterial overgrowth in patients with blind-loop syndrome. Aliment Pharmacol Ther. 2005;21(8):985–992.
   PubMedGoogle Scholar
• King CE, Toskes PP. Small intestine bacterial overgrowth. Gastroenterology 1979;76:1035–1055.
   PubMed Web of Science ®Google Scholar
• Di Baise J. Nutritional consequences of small intestinal bacterial overgrowth. Pract Gastroenterol. 2008;12:15–28.
   Google Scholar
• Grace E, Shaw C, Whelan K, et al. Review article: small intestinal bacterial overgrowth-prevalence, clinical features, current and developing diagnostic tests, and treatment. Aliment Pharmacol Ther. 2013;38:674–688.
   PubMed Web of Science ®Google Scholar
• Erdogan A, Rao SS, Gulley D, et al. Small intestinal bacterial overgrowth: duodenal aspiration vs glucose breath test. Neurogastroenterol Motil. 2015;27:481–489.
   PubMed Web of Science ®Google Scholar
• Quigley EMM. The spectrum of small intestinal bacterial overgrowth (SIBO). Curr Gastroenterol Rep. 2019;21:3.
   PubMedGoogle Scholar
• Khoshini R, Dai S-C, Lezcano S, et al. A systematic review of diagnostic tests for small intestinal bacterial overgrowth. Dig Dis Sci. 2008;53:1443–1454.
   PubMed Web of Science ®Google Scholar
• Shah SC, Day LW, Somsouk M, et al. Meta-analysis: antibiotic therapy for small intestinal bacterial overgrowth. Aliment Pharmacol Ther. 2013;38:925–934.
   PubMed Web of Science ®Google Scholar
• Gatta L, Scarpignato C. Systematic review with meta-analysis: rifaximin is effective and safe for the treatment of small intestine bacterial overgrowth. Aliment Pharmacol Ther. 2017;45:604–616.
   PubMed Web of Science ®Google Scholar
• Koo HL, DuPont HL. Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases. Curr Opin Gastroenterol. 2010;26:17–25
   PubMed Web of Science ®Google Scholar
• Rabenstein T, Fromm MF, Zolk O. Rifaximin a non-resorbable antibiotic with many indications in gastroenterology. Z Gastroenterol. 2011;49:211–224
   PubMedGoogle Scholar
• Sachdev AH, Pimentel M. Antibiotics for irritable bowel syndrome: rationale and current evidence. Curr Gastroenterol Rep. 2012;14:439–445
   PubMedGoogle Scholar
• Singh VV, Toskes PP. Small bowel bacterial overgrowth: presentation, diagnosis, and treatment. Curr Gastroenterol Rep. 2003;5:365–372
   PubMedGoogle Scholar
• Ponziani FR, Gerardi V, Gasbarrini A. Diagnosis and treatment of small intestinal bacterial overgrowth. Expert Rev Gastroenterol Hepatol. 2016;10:215–227
   PubMed Web of Science ®Google Scholar
• Bohm M, Siwiec RM, Wo JM. Diagnosis and management of small intestinal bacterial overgrowth. Nutr Clin Pract. 2013;28:289–299
   PubMed Web of Science ®Google Scholar
• Pimentel M, Constantino T, Kong Y, et al. A 14-day elemental diet is highly effective in normalizing the lactulose breath test. Dig Dis Sci. 2004;49:73–77.
   PubMed Web of Science ®Google Scholar
• Gu L, Ding C, Tian H, et al. serial frozen fecal microbiota transplantation in the treatment of chronic intestinal pseudo-obstruction: a preliminary study. J Neurogastroenterol Motil. 2017;23:289–297.
   PubMedGoogle Scholar
• Lauritano EC, Gabrielli M, Scarpellini E, et al. Small intestinal bacterial overgrowth recurrence after antibiotic therapy. Am J Gastroenterol. 2008;103:2031–2035.
   PubMed Web of Science ®Google Scholar
• Cogliandro RF, Antonucci A, De Giorgio R, et al. Patient-reported outcomes and gut dysmotility in functional gastrointestinal disorders. Neurogastroenterol Motil. 2011;23:1084–1091.
   PubMed Web of Science ®Google Scholar
• Lauro A, De Giorgio R, Pinna AD. Advancement in the clinical management of intestinal pseudo-obstruction. Expert Rev Gastroenterol Hepatol. 2015;9:197–208.
   PubMed Web of Science ®Google Scholar
• Olden KW. The use of antidepressants in functional gastrointestinal disorders: new uses for old drugs. CNS Spectr. 2005;10:891–896.
   PubMed Web of Science ®Google Scholar
• McQuay HJ, Tramèr M, Nye BA, et al. A systematic review of antidepressants in neuropathic pain. Pain 1996;68:217–227.
   PubMed Web of Science ®Google Scholar
• Watson CP, Vernich L, Chipman M, et al. Nortriptyline versus amitriptyline in postherpetic neuralgia: a randomized trial. Neurology 1998;51:1166–1171.
   PubMed Web of Science ®Google Scholar
• Moore RA, Derry S, Aldington D, et al. Amitriptyline for neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2012;12:CD008242.
   PubMedGoogle Scholar
• Gajraj NM. Pregabalin: its pharmacology and use in pain management. Anesth Analg. 2007;105:1805–1815.
   PubMed Web of Science ®Google Scholar
• Lee KJ, Kim JH, Cho SW. Gabapentin reduces rectal mechano-sensitivity and increases rectal compliance in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2005;22:981–988.
   PubMed Web of Science ®Google Scholar
• Black CJ, Yuan Y, Selinger CP, et al. Efficacy of soluble fiber, antispasmodic drugs, and gut-brain neuromodulators in irritable bowel syndrome: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2020;5:117–131.
   PubMed Web of Science ®Google Scholar
• De Giorgio R, Zucco FM, Chiarioni G, et al. Management of opioid-induced constipation and bowel dysfunction: expert opinion of an Italian multidisciplinary panel. Adv Ther. 2021;38:3589–3621.
   PubMed Web of Science ®Google Scholar
• Thomas J. Opioid-induced bowel dysfunction. J Pain Symptom Manage. 2008;35:103–113.
   PubMed Web of Science ®Google Scholar
• Green JM, Sundman MH, Chou YH. Opioid-induced microglia reactivity modulates opioid reward, analgesia, and behavior. Neurosci Biobehav Rev. 2022;135:104544.
   PubMed Web of Science ®Google Scholar
• Prapaitrakool S, Hollmann MW, Wartenberg HC, et al. Use of buprenorphine in children with chronic pseudo-obstruction syndrome: case series and review of literature. Clin J Pain. 2012;28:722–725.
   PubMed Web of Science ®Google Scholar
• Zemrani B, Lambe C, Goulet O. Cannabinoids improve gastrointestinal symptoms in a parenteral nutrition-dependent patient with chronic intestinal pseudo-obstruction. J Parenter Enteral Nutr. 2021;45:427–429
   PubMedGoogle Scholar
• De Giorgio R, Camilleri M. Human enteric neuropathies: morphology and molecular pathology. Neurogastroenterol Motil. 2004;16:515–531.
   PubMedGoogle Scholar
• De Giorgio R, Guerrini S, Barbara G, et al. Inflammatory neuropathies of the enteric nervous system. Gastroenterology 2004;126:1872–1883.
   PubMed Web of Science ®Google Scholar
• Yang CW, Kao YC, Lin PC, et al. Case report: proteinase 3 antineutrophil cytoplasmic antibody-associated ulcerative colitis presenting as recurrent intestinal pseudo-obstruction in a teenage patient with in situ proteinase 3 immunohistochemical staining. Front Pediatr. 2022;10:822491.
   PubMedGoogle Scholar
• Hubball AW, Lang B, Souza MA, et al. Voltage-gated potassium channel (K(v) 1) autoantibodies in patients with chagasic gut dysmotility and distribution of K(v) 1 channels in human enteric neuromusculature (autoantibodies in GI dysmotility). Neurogastroenterol Motil. 2012;24(719–728):e344.
   PubMedGoogle Scholar
• Joly F, Amiot A, Messing B. Nutritional support in the severely compromised motility patient: when and how? Gastroenterol Clin North Am. 2011;40:845–851.
   PubMedGoogle Scholar
• Kirby DF, Raheem SA, Corrigan ML. Nutritional interventions in chronic intestinal pseudo-obstruction. Gastroenterol Clin North Am. 2018;47:209–218.
   PubMedGoogle Scholar
• Amiot A, Joly F, Alves A, et al. Long-term outcome of chronic intestinal pseudo-obstruction adult patients requiring home parenteral nutrition. Am J Gastroenterol. 2009;104:1262–1270.
   PubMed Web of Science ®Google Scholar
• Lacy BE, Loew BJ. Diagnosis, treatment and nutritional management of chronic intestinal pseudo-obstruction. Pract Gastroenterol. 2009;8:9–24
   Google Scholar
• Cucchiara S, Borrelli O. Nutritional challenge in pseudo-obstruction: the bridge between motility and nutrition. J Pediatr Gastroenterol Nutr. 2009;48:S83–S85.
   PubMed Web of Science ®Google Scholar
• Benjamin J, Singh N, Makharia GK. Enteral nutrition for severe malnutrition in chronic intestinal pseudo-obstruction. Nutrition 2010;26:502–505.
   PubMed Web of Science ®Google Scholar
• Mueller C, Compher C, Druyan ME; the American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.) Board of Directors. A.S.P.E.N. clinical guidelines nutrition screening, assessment, and intervention in adults. J PEN J Parenter Enteral Nutr. 2011;35:16–24.
   PubMed Web of Science ®Google Scholar
• Billiauws L, Corcos O, Joly F. Dysmotility disorders: a nutritional approach. Curr Opin Clin Nutr Metab Care. 2014;17:483–488.
   PubMedGoogle Scholar
• Dutton DH, Harrell SP, Wo JM. Diagnosis and management of adult patients with chronic intestinal pseudo-obstruction. Nutr Clin Pract. 2006;21:16–22
   PubMedGoogle Scholar
• Watanabe S, Tsujino S. Applications of medium-chain triglycerides in foods. Front Nutr. 2022;9:802805.
   PubMedGoogle Scholar
• Camilleri M, Phillips SF. Acute and chronic intestinal pseudo-obstruction. Adv Intern Med. 1991;36:287–306
   PubMedGoogle Scholar
• Pironi L, Joly F, Forbes A, et al. Long-term follow-up of patients on home parenteral nutrition in Europe: implication for intestinal transplantation. Gut 2011;60:17–25.
   PubMed Web of Science ®Google Scholar
• Pironi L, Arends J, Bozzetti F, et al. Home artificial nutrition and chronic intestinal failure special interest group of ESPEN. ESPEN guidelines on chronic intestinal failure in adults. Clin Nutr. 2016;35:247–307.
   PubMed Web of Science ®Google Scholar
• Scolapio JS, Ukleia A, Bouras EP, et al. Nutritional management of chronic intestinal pseudo-obstruction. J Clin Gastroenterol. 1999;28:306–312.
   PubMed Web of Science ®Google Scholar
• Ohkubo H, Inoh Y, Fuyuki A, et al. Chronic intestinal pseudo-obstruction. Nihon Rinsho. 2015;73:875–883
   PubMedGoogle Scholar
• Ohkubo H, Fuyuki A, Arimoto J, et al. Efficacy of percutaneous endoscopic gastro-jejunostomy (PEG-J) decompression therapy for patients with chronic intestinal pseudo-obstruction (CIPO). Neurogastroenterol Motil. 2017;29.
   Google Scholar
• Di Lorenzo C, Flores AF, Buie T, et al. Intestinal motility and jejunal feeding in children with chronic intestinal pseudo-obstruction. Gastroenterology. 1995;108:1379–1385.
   PubMedGoogle Scholar
• Gariepy CE, Mousa H. Clinical management of motility disorders in children. Semin Pediatr Surg. 2009;18:224–238.
   PubMedGoogle Scholar
• Ukleja A, Romano MM. Complications of parenteral nutrition. Gastroenterol Clin North Am. 2007;36:23–46.
   PubMed Web of Science ®Google Scholar
• Worthington P, Balint J, Bechtold M, et al. When is parenteral nutrition appropriate? JPEN J Parenter Enteral Nutr. 2017;41:324–377
   PubMed Web of Science ®Google Scholar
• Pironi L, Goulet O, Buchman A, et al.; Home artificial nutrition and chronic intestinal failure working group of ESPEN. Outcome on home parenteral nutrition for benign intestinal failure: a review of the literature and benchmarking with the European prospective survey of ESPEN. Clin Nutr. 2012;31:831–845.
   PubMed Web of Science ®Google Scholar
• Bielawska B, Allard JP. Parenteral nutrition and intestinal failure. Nutrients 2017;9:466.
   PubMed Web of Science ®Google Scholar
• Beath SV, Kelly DA. Total parenteral nutrition-induced cholestasis: prevention and management. Clin Liver Dis. 2016;20:159–176.
   PubMedGoogle Scholar
• Conley TE, Lal S. Nutritional considerations in severe primary chronic small intestinal dysmotility. Curr Opin Clin Nutr Metab Care. 2021;24:433–439.
   PubMedGoogle Scholar
• Gulliver EL, Young RB, Chonwerawong M, et al. Review article: the future of microbiome-based therapeutics. Aliment Pharmacol Ther. 2022;56:192–208.
   PubMedGoogle Scholar
• Lacy BE, Pimentel M, Brenner DM, et al. ACG clinical guideline: management of irritable bowel syndrome. Am J Gastroenterol. 2021;116:17–44.
   PubMed Web of Science ®Google Scholar
• Rueckert H, Ganz J. How to heal the gut’s brain: regeneration of the enteric nervous system. Int J Mol Sci. 2022;23:4799.
   PubMedGoogle Scholar
• Bianco F, Lattanzio G, Lorenzini L, et al. Enteric neuromyopathies: highlights on genetic mechanisms underlying chronic intestinal pseudo-obstruction. Biomolecules. 2022;12:1849.
   PubMedGoogle Scholar